Business Development Gene Genetics 
Pharmaceutical Technology
JUNE 19, 2023
Although only a small number of gene therapies have reached the market thus far, the industry is poised to grow quickly over the next few years. According to GlobalData’s clinical trials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone.
Pharmaceutical Technology
JULY 29, 2022
However, in patients with urea cycle disorders, genetic defects result in inadequate amounts of the enzymes needed to convert nitrogen into urea. The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder. Future Possibilities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 13, 2020
.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.
pharmaphorum
SEPTEMBER 21, 2021
In other cases, rare CNS conditions may be passed on from one generation to the next without knowledge or understanding that the reason for suffering or death among previous generations was genetic in basis and therefore identifiable, and perhaps even treatable. This is and should be a priority for our health system. About the author.
pharmaphorum
OCTOBER 12, 2022
Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. and France to accelerate the development of genomic therapies.
pharmaphorum
AUGUST 8, 2022
The GBT deal comes at a time when the market for SCD therapies is undergoing significant change, with multiple new drugs reaching the market after years of stagnation and progress also being made with genetic therapies from the likes of bluebird bio, Vertex Pharma/CRISPR Therapeutics and Precision Bio/Novartis.
Imperical Blog
MAY 20, 2020
Dan McDonald, vice president, global business development. Imogen Cheese, Imperial director of business development, U.K. Wearables will be developed that notify patients and EMS services of precursors to adverse events. Gene counselors and genetic testing. and Europe. Expanded-purpose wearables.
Expert insights. Personalized for you.
130 
Let's personalize your content